Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Recruiting now · Phase 2
Conditions studied: Multiple Myeloma
In brief
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection（BCMA CAR-T） Therapy for R/R MM. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of BCMA CAR+ T cells.
Key facts
- Study ID
- NCT05594797
- Run by
- Hrain Biotechnology Co., Ltd.
- People needed
- 100
- Starts
- 2022-07-12
- Expected to finish
- 2027-07-31
- Last updated by the study team
- 2022-12-09
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Shanghai Changzheng Hospital — Shanghai, Shanghai Municipality, China (enrolling)
- The First Affiliated Hospital of Wenzhou Medical University — Wenzhou, Zhejiang, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.